These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1926144)

  • 21. Recognition, diagnosis, and management of Wilson's disease.
    Brewer GJ
    Proc Soc Exp Biol Med; 2000 Jan; 223(1):39-46. PubMed ID: 10632959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment and management of Wilson's disease.
    Shimizu N; Yamaguchi Y; Aoki T
    Pediatr Int; 1999 Aug; 41(4):419-22. PubMed ID: 10453198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of presymptomatic Wilson's disease.
    Walshe JM
    Lancet; 1988 Aug; 2(8608):435-7. PubMed ID: 2900362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
    Gibbs K; Walshe JM
    Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Drug Managements of Wilson's Disease: From West to East.
    Li WJ; Chen C; You ZF; Yang RM; Wang XP
    Curr Neuropharmacol; 2016; 14(4):322-5. PubMed ID: 26639459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of Wilson's disease recovering from severe brain damage--special reference to trientine and D-penicillamine therapy].
    Ishitsu T; Chikazawa S
    No To Hattatsu; 1989 May; 21(3):294-6. PubMed ID: 2736129
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical considerations for an effective medical therapy in Wilson's disease.
    Weiss KH; Stremmel W
    Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pregnancy in a patient treated with trientine dihydrochloride for Wilson's disease].
    Desbriere R; Roquelaure B; Sarles J; Boubli L
    Presse Med; 1998 May 2-9; 27(17):806. PubMed ID: 9767885
    [No Abstract]   [Full Text] [Related]  

  • 31. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract]   [Full Text] [Related]  

  • 32. Trientine-induced neurological deterioration in a patient with Wilson's disease.
    Kim B; Chung SJ; Shin HW
    J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
    Dzieżyc K; Litwin T; Chabik G; Członkowska A
    Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
    Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
    J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wilson's disease in one identical twin and treatment by triethylene tetramine 2HCl in another case.
    Watson RG
    Ulster Med J; 1983; 52(1):48-53. PubMed ID: 6687321
    [No Abstract]   [Full Text] [Related]  

  • 37. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
    Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
    Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
    [No Abstract]   [Full Text] [Related]  

  • 38. Copper chelating agents. A comparison of cupruretic responses to various tetramines and D-penicillamine.
    Borthwick TR; Benson GD; Schugar HJ
    J Lab Clin Med; 1980 Apr; 95(4):575-80. PubMed ID: 7359013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.
    Walshe JM
    Lancet; 1969 Dec; 2(7635):1401-2. PubMed ID: 4188283
    [No Abstract]   [Full Text] [Related]  

  • 40. Acquired sideroblastic anaemia induced by a copper-chelating agent.
    Perry AR; Pagliuca A; Fitzsimons EJ; Mufti GJ; Williams R
    Int J Hematol; 1996 Jul; 64(1):69-72. PubMed ID: 8757970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.